At the same time, we've strengthened our digital capabilities. We have genomic data, clinical data, AI, and clinical practice all connected within one system. That allows us to take a much more targeted approach to population health while helping us identify the right strategic partnerships.
Our priority is simple: to help people live longer, healthier, and more fulfilling lives. Abu Dhabi has become what we call a living laboratory, where partners can accelerate opportunities to build, test and scale next-generation healthcare solutions.
"Partnerships are at the heart of everything we do because no single organization can transform healthcare alone." — Dr. Noura Al Ghaithi
Pharm Exec: Partnerships seem to be central to that vision. What are you looking for in collaborators?
Dr. Al Ghaithi: No one can achieve this level of ambition alone. Abu Dhabi’s progress is rooted in long-term, trusted partnerships with organizations across the globe whose priorities align with ours.
We're opening Abu Dhabi to these partners by providing access to our infrastructure, AI capabilities, and data so they can evaluate innovations in areas such as biotechnology, medical technology, drug discovery, and digital health. It's a mutually beneficial model because companies can validate solutions in a real-world environment while helping improve healthcare for our population.
Pharm Exec: What makes Abu Dhabi's model different from other life sciences hubs represented here at BIO?
Dr. Al Ghaithi: The biggest differentiator is that the system itself is innovative. Everything is connected. Data, research, regulation, policy, healthcare providers, and investment organizations all work together rather than operating in silos.
Our integrated digital platform connects hospitals and clinics, giving physicians a comprehensive view of patient information while allowing us to better understand population health risks. Combined with one of the world's most diverse genomic programs, that creates an environment where innovation can move much more quickly.
Pharm Exec: How is that integrated approach translating into industry growth?
Dr. Al Ghaithi: We're already seeing tangible results. Pharmaceutical companies are establishing manufacturing operations in Abu Dhabi to serve regional and global markets. Clinical trial activity has increased by 300% over the past two years, and we're building a trusted research environment that gives partners secure access to high-quality data supported by AI and advanced digital capabilities.
This isn't something we're hoping to achieve years from now. This is already happening. The infrastructure exists today, and we're focused on helping companies generate evidence, validate technologies, and bring innovations to patients faster.
Pharm Exec: Looking ahead, what is your long-term vision for Abu Dhabi's life sciences sector?
Dr. Al Ghaithi: We want Abu Dhabi to be recognized as a trusted global partner for life sciences innovation. By combining integrated data, AI, research, healthcare delivery, and international collaboration, we're creating an environment where discoveries can move efficiently from concept to real-world impact. That's the model we're continuing to build.
